Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Terns Pharmaceuticals (TERN)
NASDAQ:TERN
RESEARCH TOOLSreports
Terns Pharmaceuticals (TERN) Stock Price & Analysis
156 Followers
TERN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.26 - $8.75
Previous Close$6.85
Volume1.32M
Average Volume (3M)1.06M
Market Cap
$443.04M
Enterprise Value$202.81M
Total Cash (Recent Filing)$240.65M
Total Debt (Recent Filing)$427.00K
Price to Earnings (P/E)―
Beta0.16
Next Earnings
Aug 06, 2024EPS Estimate
-$0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.26
Shares Outstanding64,677,145
10 Day Avg. Volume1,246,898
30 Day Avg. Volume1,060,022
Standard Deviation0.31
R-Squared0.00465
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)1.81
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.05
Forecast
1Y Price Target
$14.30Price Target Upside112.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Terns Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPositive read-throughs for TERN-701, an allosteric BCR-ABL1 inhibitor for CML with potential to be similar, if not better, than Scemblix.
Financial PerformanceTerns Pharmaceuticals' 1Q24 cash balance of $241M provides runway into 2026.
Market PotentialThe obesity space continues to garner significant investor interest, and the potential opportunity for TERN-601 as an oral option in the category is promising.
Bears Say
Clinical TrialsZealand Pharmaceuticals announced what was viewed to be disappointing Phase 2 data for dapiglutide.
Executive ChangesThe increase in SG&A was primarily due to a one-time expense related to executive leadership transition in the CEO position.
Financial PerformanceTERN reported a net loss of $21MM for the fourth quarter and $90.2MM for the full year.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TERN FAQ
What was Terns Pharmaceuticals’s price range in the past 12 months?
Terns Pharmaceuticals lowest stock price was $3.26 and its highest was $8.75 in the past 12 months.
What is Terns Pharmaceuticals’s market cap?
Currently, no data Available
When is Terns Pharmaceuticals’s upcoming earnings report date?
Terns Pharmaceuticals’s upcoming earnings report date is Aug 06, 2024 which is in 34 days.
How were Terns Pharmaceuticals’s earnings last quarter?
Terns Pharmaceuticals released its earnings results on May 13, 2024. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.346 by $0.046.
Is Terns Pharmaceuticals overvalued?
According to Wall Street analysts Terns Pharmaceuticals’s price is currently Undervalued.
Does Terns Pharmaceuticals pay dividends?
Terns Pharmaceuticals does not currently pay dividends.
What is Terns Pharmaceuticals’s EPS estimate?
Terns Pharmaceuticals’s EPS estimate is -$0.33.
How many shares outstanding does Terns Pharmaceuticals have?
Terns Pharmaceuticals has 64,677,150 shares outstanding.
What happened to Terns Pharmaceuticals’s price movement after its last earnings report?
Terns Pharmaceuticals reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.346. Following the earnings report the stock price went up 5.935%.
Which hedge fund is a major shareholder of Terns Pharmaceuticals?
Among the largest hedge funds holding Terns Pharmaceuticals’s share is Fairmount Funds Management Llc. It holds Terns Pharmaceuticals’s shares valued at 13M.
---
Terns Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.30 (112.80% Upside)
$14.30 (112.80% Upside)
Blogger Sentiment
Bullish
TERN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 852.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 3.0%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.71%
12-Months-Change
Fundamentals
Return on Equity
-34.73%
Trailing 12-Months
Asset Growth
-18.10%
Trailing 12-Months
Company Description
Terns Pharmaceuticals
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases.
---
TERN Stock 12 Month Forecast
Average Price Target
$14.30
▲(112.80% Upside)
Technical Analysis
Best Analysts Covering TERN
1 Year
1 Year Success Rate
5/8 ratings generated profit
1 Year Average Return
+13.58%
reiterated a buy rating 2 months ago
Copying Etzer Darout's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +13.58% per trade.
---